Skip to main content
SpringerLink
Log in

Somatostatin Receptor Imaging

  • Chapter
Somatostatin

Part of the book series: Endocrine Updates ((ENDO,volume 24))

Conclusions and Perspective

[111In-DTPA0]-octreotide is a radiopharmaceutical with a great potential for the visualization of SSTR positive tumors. The overall sensitivity of SRI to localize neuroendocrine tumors is high. In a number of neuroendocrine tumor types, inclusion of SRI in the localization or staging procedure may be very rewarding, either in terms of cost-effectiveness, patient management, or quality of life. The value of SRI in patients with other tumors, like breast cancer, malignant lymphomas, or in patients with granulomatous diseases, has to be established. The development of PRRT is expected to stimulate peptide receptor imaging.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Patel Y.C., Amherdt M., Orci L. Quantitative electron microscopic autoradiography of insulin, glucagon and somatostatin binding sites on islets. Science 1982; 217:1155–6.

    CAS  PubMed  Google Scholar 

  2. Reubi J.C., Kvols L.K., Waser B., et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50:5969–77.

    CAS  PubMed  Google Scholar 

  3. Sreedharan S.P., Kodama K.T., Peterson K.E., Goetzl E.J. Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 1989; 264:949–53.

    CAS  PubMed  Google Scholar 

  4. Reubi J.C., Waser B., Vanhagen M., et al. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Canc 1992; 50:895–900.

    CAS  Google Scholar 

  5. Van Uden A., Steinmeijer M.V.J., De Swart J., et al. Imaging with octreoscan: haste makes waste. Eur J Nucl Med 1999; 26:1022.

    Google Scholar 

  6. Reubi J.C., Horisberger U., Studer U.E., Wascr B., Laissue JA. Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. J Clin Endocrinol Metab 1993; 77:1323–28.

    Article  CAS  PubMed  Google Scholar 

  7. Gibril F., Reynolds J.C., Chen C.C., et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999; 40:539–53.

    CAS  PubMed  Google Scholar 

  8. Plockinger U., Reichel M., Fett U., Saeger W., Quabbe H.J. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 1994; 79:1416–23.

    Article  CAS  PubMed  Google Scholar 

  9. Legovini P., De Menis E., Billed D., et al. 111 Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients. J Endocrinol Invest 1997; 20:424–8.

    CAS  PubMed  Google Scholar 

  10. Oppizzi G., Cozzi R., Dallabonzana D., et al. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors. J Endocrinol Invest 1998; 21:512–9.

    CAS  PubMed  Google Scholar 

  11. Kwekkeboom D.J., de Herder W.W., Krenning E.P. Receptor imaging in the diagnosis and treatment of pituitary tumors. J Endocrinol Invest 1999; 22:80–8.

    CAS  PubMed  Google Scholar 

  12. De Bruin T.W.A., Kwekkeboom D.J., Van’ t Verlaat J.W., et al. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab 1992; 75:1310–7.

    PubMed  Google Scholar 

  13. Merola B., Colao A., Ferone D., et al. Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas. Horm Res 1993; 40:149–55.

    CAS  PubMed  Google Scholar 

  14. Kwekkeboom D.J., Krenning E.P., Oei H.Y., van Eyck C.H.J., Lamberts S.W.J. Use of radiolabeled somatostatin to localize islet cell tumors. In: Mignon M., Jensen R.T., eds. Frontiers of gastro-intestinal research, Vol 23. Endocrine tumors of the pancreas. New York: Karger, 1995: pp 298–308.

    Google Scholar 

  15. Cadiot G., Lebtahi R., Sarda L., et al. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Gastroenterology 1996; 111:845–54.

    Article  CAS  PubMed  Google Scholar 

  16. De Kerviler E., Cadiot G., Lebtahi R., Faraggi M., Le Guludec D., Mignon M. Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. Eur J Nucl Med 1994; 21:1191–7.

    Article  PubMed  Google Scholar 

  17. Gibril F., Reynolds J.C., Doppman J.L., et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125:26–34.

    CAS  PubMed  Google Scholar 

  18. Zimmer T., Stolzel U., Bader M., et al. Endoscopie ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 1996; 39:562–8.

    CAS  PubMed  Google Scholar 

  19. Alexander H.R., Fraker D.L., Norton J.A., et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998; 228:228–38.

    Article  CAS  PubMed  Google Scholar 

  20. Lunderquist A. Radiologie diagnosis of neuroendocrine tumors. Acta Oncol 1989; 28:371–2.

    CAS  PubMed  Google Scholar 

  21. Doherty G.M., Doppman J.L., Shawker T.H., et al. Results of a prospective strategy to diagnose, localize, and resect insulinomas. Surgery 1991; 110:989–97.

    CAS  PubMed  Google Scholar 

  22. Rösch T., Lightdale C.J., Botet J.F., et al. Localization of pancreatic endocrine tumors by endoscopie ultrasonography. N Engl J Med 1992; 326:1721–6.

    PubMed  Google Scholar 

  23. Lebtahi R., Cadiot G., Sarda L., et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997; 38:853–8.

    CAS  PubMed  Google Scholar 

  24. Termanini B., Gibril F., Reynolds J.C., et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997; 112:335–47.

    Article  CAS  PubMed  Google Scholar 

  25. Lamberts S.W.J., Hofland L.J., Van Koetsveld P.M., et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors. Consequences with regard to diagnosis, localisation and therapy. J Clin Endocrinol Metab 1990; 71:566–74.

    CAS  PubMed  Google Scholar 

  26. Kwekkeboom D.J., Krenning E.P., Bakker W.H., et al. Somatostatin analogue scintigraphy in carcinoid tumors. Eur J Nucl Med 1993; 20:283–92.

    Article  CAS  PubMed  Google Scholar 

  27. Westlin J.E., Janson E.T., Arnberg H., Ahlstrom H., Oberg K., Nilsson S. Somatostatin receptor scintigraphy of carcinoid tumours using the [111 In-DTPA-D-Phel]-octreotide. Acta Oncol 1993; 32:783–6.

    CAS  PubMed  Google Scholar 

  28. Schillaci O., Scopinaro F., Angeletti S., et al. SPECT improves accuracy of Somatostatin receptor scintigraphy in abdominal carcinoid tumors. J Nucl Med 1996; 37:1452–6.

    CAS  PubMed  Google Scholar 

  29. Ahlman H., Wängberg B., Tisell L.E., Nilsson O., Fjälling M., Forssell-Aronsson E. Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection. Br J Surg 1994; 81:1144–9.

    CAS  PubMed  Google Scholar 

  30. Kvols L.K., Moertel C.G., O’Connell M.J., et al. Treatment of the malignant carcinoid syndrome. N Eng J Med 1986; 315:663–6.

    CAS  Google Scholar 

  31. Kvols L.K. Medical oncology considerations in patients with metastatic neuroendocrine carcinomas. Semin Oncol 1994; 21(suppl 13):56–60.

    CAS  PubMed  Google Scholar 

  32. Kwekkeboom D.J., Van Urk H., Pauw K.H., et al. Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 1993; 34:873–8.

    CAS  PubMed  Google Scholar 

  33. Kwekkeboom D.J., Reubi J.C., Lamberts S.W.J., et al. In vivo Somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993; 76:1413–7.

    Article  CAS  PubMed  Google Scholar 

  34. Tisell L.E., Ahlman H., Wängberg B., et al. Somatostatin receptor scintigraphy in medullary thyroid carcinoma. Br J Surg 1997; 84:543–7.

    Article  CAS  PubMed  Google Scholar 

  35. Berna L., Chico A., and Matias-Guiu X., et al. Use of Somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. Eur J Nucl Med 1998; 25:1482–8.

    CAS  PubMed  Google Scholar 

  36. Adams S., Baum R.P., Hertel A., Schumm-Draeger P.M., Usadel K.H., Hör G. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 1998; 25:1277–83.

    CAS  PubMed  Google Scholar 

  37. Postema P.T.E., De Herder W.W., Reubi J.C., et al. Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion 1996; 1(suppl):36–7.

    Google Scholar 

  38. Baudin E., Schlumberger M., Lumbroso J., Travagli J.P., Caillou B., Parmentier C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 1996; 81:2541–4.

    Article  CAS  PubMed  Google Scholar 

  39. Gulec S.A., Serafini A.N., Sridhar K.S., et al. Somatostatin receptor expression in Hurthle cell cancer of the thyroid. J Nucl Med 1998; 39:243–5.

    CAS  PubMed  Google Scholar 

  40. Kwekkeboom D.J., Kho G.S., Lamberts S.W., Reubi J.C., Laissue J.A., Krenning E.P. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994; 21:1106–13.

    Article  CAS  PubMed  Google Scholar 

  41. O’Byrne K.J., Ennis J.T., Freyne P.J., Clancy L.J., Prichard J.S., Carney D.N. Scintigraphic imaging of small-cell lung cancer with [111]pentetreotide, a radiolabelled Somatostatin analogue. Br J Cancer 1994; 69:762–6.

    CAS  PubMed  Google Scholar 

  42. Bombardieri E., Crippa F., Cataldo I., et al. Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111n-DTPA octreotide scintigraphy. Eur J Cancer 1995; 31A: 184–8.

    CAS  PubMed  Google Scholar 

  43. Berenger N., Moretti J.L., Boaziz C., Vigneron N., Morere J.F., Breau J.L. Somatostatin receptor imaging in small cell lung cancer. Eur J Cancer 1996; 32A:1429–31.

    CAS  PubMed  Google Scholar 

  44. Reisinger I., Bohuslavitzki K.H., Brenner W., et al. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med 1998; 39:224–7.

    CAS  PubMed  Google Scholar 

  45. Kirsch C.M., von Pawel J., Grau I., Tatsch K. Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma. Eur J Nucl Med 1994; 21:1318–25.

    CAS  PubMed  Google Scholar 

  46. Kwekkeboom D.J., Lamberts S.W.J., Habbema J.D., Krenning E.P. Cost-effectiveness analysis of Somatostatin receptor scintigraphy. J Nucl Med 1996; 37:886–92.

    CAS  PubMed  Google Scholar 

  47. Van Eijck C.H., Krenning E.P., Bootsma A., et al. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 1994; 343:640–3.

    PubMed  Google Scholar 

  48. Van Hagen P.M., Krenning E.P., Reubi J.C., et al. Somatostatin analogue scintigraphy of malignant lymphomas. Br J Haemat 1993; 83:75–9.

    Google Scholar 

  49. Van den Anker-Lugtenburg P.J., Krenning E.P., Oei H.Y., et al. Somatostatin receptor scintigraphy in the initial staging of Hodgkin’s disease. Br J Haematol 1996; 93:96–103.

    PubMed  Google Scholar 

  50. Hoefnagel C.A., Rankin E.M., Valdés Olmos R.A., Israëls S.P., Pavel S., Janssen A.G.M. Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamide and indium-111 pentetreotide. Eur J Nucl Med 1994; 21:587–8.

    CAS  PubMed  Google Scholar 

  51. Krenning E.P., Kwekkeboom D.J., Bakker W.H., et at. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr-3-]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716–31.

    Article  CAS  PubMed  Google Scholar 

  52. Tenenbaum F., Lumbroso J., Schlumberger M., et al. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 1995; 36:1–6.

    CAS  PubMed  Google Scholar 

  53. De Herder W.W., Krenning E.P., Malchoff C.D., et al. Somatostatin receptor scintigraphy: its value in tumor localization in patients with the Cushing syndrome caused by ectopic cortictropin and/or CRH secretion. Am J Med 1994; 96:305–12.

    PubMed  Google Scholar 

  54. Philipponneau M., Nocaudie M., Epelbaum J., et al. Somatostatin analogs for the localization and preoperativc treatment of an ACTH-secreting bronchial carcinoid tumor. J Clin Endocrinol Metab 1994; 78:20–4.

    Google Scholar 

  55. Weiss M., Yellin A., Husza’r M., Eisenstein Z., Bar-Zif J., Krausz Y. Localization of adrenocorticotropic hormone-secreting bronchial carcinoid tumor by somatostatin-receptor scintigraphy. Ann Intern Med 1994; 121:198–9.

    CAS  PubMed  Google Scholar 

  56. Torpy D.J., Chen C.C., Mullen N., et al. Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients. J Clin Endocrinol Metab 1999; 84:1186–92.

    CAS  PubMed  Google Scholar 

  57. Haldemann A.R., Rosier H., Barth A., et al. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability. J Nucl Med 1995; 36:403–10.

    CAS  PubMed  Google Scholar 

  58. Schmidt M., Scheidhauer K., Luyken C., et al. Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 1998; 25:675–86.

    Article  CAS  PubMed  Google Scholar 

  59. Reubi J.C., Horisberger U., Lang W., Koper J.W., Braakman R., Lamberts S.W.J. Coincidence of EGF receptors and Somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol 1989; 134;337–44.

    CAS  PubMed  Google Scholar 

  60. Vanhagen P.M., Krenning E.P., Reubi J.C., et al. Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med 1994; 21:497–502.

    Article  CAS  PubMed  Google Scholar 

  61. Postema P.T.E., Krenning E.P., Wijngaarde R., et al. [111In-DTPA-D-Phe1]-octrcotidc scintigraphy in thyroidaal and orbital Graves’ disease: a parameter for disease activity? J Clin Endocrinol Metab 1994; 79:1845–51.

    Article  CAS  PubMed  Google Scholar 

  62. Krassas G.E., Dumas A., Pontikides N., Kaltsas T. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf) 1995; 42:571–80.

    CAS  Google Scholar 

  63. Kahaly G., Görges R., Diaz M., Hommel G., Bockisch A. Indium-111-pentetreotide in Graves’ disease. J Nucl Med 1998; 39:533–6.

    CAS  PubMed  Google Scholar 

  64. Kwekkeboom D.J., Krenning E.P., Kho G.S., Breeman W.A.P., Van Hagen P.M. Octreotide scintigraphy in patients with sarcoidosis. Eur J Nucl Med 1998; 25:1284–92.

    Article  CAS  PubMed  Google Scholar 

  65. Lebtahi R., Crestani B., Belmaloug N., et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med 2001; 42:21–6.

    CAS  PubMed  Google Scholar 

  66. Reubi J.C., Waser B., Friess H., Krenning E.P., Büchler M., Laissue J. Regulatory peptide receptors in goiters of the human thyroid. J Nucl Med 1997; 38(suppl):266P.

    Google Scholar 

  67. Gerding M.N., van der Zant F.M., van Royen E.A., et al. Octreotide-scintigraphy is a disease-activity parameter in Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 1999; 50:373–9.

    Article  CAS  Google Scholar 

  68. Modlin I.M., Cornelius E., Lawton G.P. Use of an isotopic Somatostatin receptor probe to image gut endocrine tumors. Arch Surg 1995; 130:367–73.

    CAS  PubMed  Google Scholar 

  69. Wangberg B., Forssell-Aronsson E., Tisell L.E., Nilsson O., Fjalling M., Ahlman H. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phel-octreotide. Br J Cancer 1996; 73:770–5.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Hospital Rotterdam, Rotterdam, The Netherlands

    Dik J. Kwekkeboom, Marion de Jong & Eric P. Krenning

Authors
  1. Dik J. Kwekkeboom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marion de Jong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eric P. Krenning
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, McGill University Heath Center, Montréal, Québec, Canada

    Coimbatore B. Srikant

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science + Business Media, Inc.

About this chapter

Cite this chapter

Kwekkeboom, D.J., de Jong, M., Krenning, E.P. (2004). Somatostatin Receptor Imaging. In: Srikant, C.B. (eds) Somatostatin. Endocrine Updates, vol 24. Springer, Boston, MA. https://doi.org/10.1007/1-4020-8033-6_13

Download citation

  • DOI: https://doi.org/10.1007/1-4020-8033-6_13

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-7799-9

  • Online ISBN: 978-1-4020-8033-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation